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Abstract 
Background- Most studies agree on the effect of magnesium sulphate in treating eclampsia or controlling 
convulsion/seizure in pregnancy but controversies still remained on the importance of magnesium sulphate 
prophylaxis in preeclampsia to prevent eclampsia and other adverse birth outcomes. 
Aim- The aim of this review was to assess the effect of magnesium sulphate prophylaxis on preeclamptic 
mothers in light of disease progression and adverse outcomes. 
Methods- A comprehensive computer-based search of the published work was done in, PubMed/MEDLINE, 
HINARI and Google scholar. Studies that assessed the effect of magnesium sulphate on prevention of eclampsia 
and maternal and perinatal birth outcomes and published only in English language were included. Studies that 
reported progression of preeclampsia to eclampsia and the effect of magnesium sulphate on birth outcomes were 
included. Statistical analyses were performed using Review Manager, version 5.3 (The Cochrane Collaboration) 
and STATA Version 11. Quantitative data were presented as risk ratios (RR) with 95% confidence intervals (CI) 
and  pooled estimates (summary RR with 95% CI) were calculated using random-effect meta-analysis. 
Results- Overall, 28002 mothers with preeclampsia were included and the individual studies were conducted in 
American, Asian, European and African countries. About 58% of the studies were randomized control trials. 
Mild preeclamptic mothers who took magnesium sulphate have similar risk of developing eclampsia as 
compared with the no magnesium sulphate counterparts (RR: 0.9, 95% CI: 0.53-1.54)). On the contrary, severe 
preeclamptic mothers who took magnesium sulphate have 66% lower risk of developing eclampsia as compared 
with the no magnesium sulphate counterparts (RR: 0.34, 95% CI:0.23-0.48)). 
Conclusion- From this systematic review and meta-analysis it can be concluded that magnesium sulphate 
prophylaxis provision for mild preeclampsia cases has no value in preventing severe preecalampsia but found to 
be effective in preventing eclampsia/convulsion in sever preeclampsia cases.  It is recommended that magnesium 
sulphate should not be given to mild and moderate preeclampsia cases in the absence of adequate evidence from 
randomized controlled trials. 
Keywords: magnesium sulphate, preeclampsia/eclampsia, convulsion  
 
INTRODUCTION 
Globally, over half a million women die each year from pregnancy related causes signifying that complications 
of pregnancy and childbirth are the leading cause of death amongst women of reproductive age[1].  Hypertensive 
disorders of pregnancy (HDP) is one of the leading causes of maternal and perinatal mortality and morbidity [2]. 
Globally 10% of women have high blood pressure during pregnancy and preeclampsia complicates 2 to 8% of 
pregnancies[1]. "Preeclampsia," a unique form of hypertension, occurs only during pregnancy characterized by 
the onset of hypertension and proteinuria, usually during the third trimester of pregnancy[3]. 
Women with hypertensive disorders of pregnancy should be offered an integrated package of care 
covering admission to hospital, measurement of blood pressure, treatment, testing for proteinuria and blood 
tests[4]. Treatment options for HDP vary according to diagnosis, severity, gestational age, the woman’s wishes 
and the consultant’s recommendations. There is a general consensus that antihypertensive treatment decreases 
morbidity and mortality in pregnant women with severe hypertension. Magnesium sulphate is  also 
recommended to use as an anticonvulsant for prevention and treatment of eclamptic patients [5].  
Studies showed that Magnesium sulphate is superior in controlling eclamptic fit as compared to other 
anticonvulsants such as phenytoin and diazepam. Maternal mortality and recurrence of convulsions were 
reported to be lower in mothers who took magnesium sulphate as compared with those who took other 
anticonvulsants [6,7, 8].  
Maternal effects of magnesium sulphate include, delay of labour progress, respiratory depression, 
cardiac arrest, flushing, nausea/vomiting, headache, generalized muscle weakness, shortness of breath  and loss 
of motor reflex. Similarly, the Fetal/Neonatal Effects of magnesium sulphate include, lethargy, hypotonia and 
respiratory depression [3]. 
Most studies agree on the effect of magnesium sulphate in treating eclampsia or controlling 
convulsion/seizure in pregnancy but controversies still remained on the importance of magnesium sulphate 
prophylaxis in preeclampsia to prevent eclampsia and other adverse birth outcomes. There are two arguments in 
this regard ; the first one recommends keeping magnesium sulphate only for eclampsia to control seizure [9,10] 
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and the second one recommends providing magnesium sulphate including in mild and moderate cases as a 
prophylaxis to prevent the occurrence of eclampsia in addition to treating eclampsia [11, 12]. Each of these 
arguments is supported by the respective justifications.  In the first case, the adverse effect of magnesium 
sulphate is higher than its beneficial effect if it is universally given as a prophylaxis and treatment, so the 
recommendation is severe cases should stay nearby to the health facilities and if convulsion occurs magnesium 
sulphate should be given immediately. Supporters of this option claim that even though magnesium sulphate is 
given, convulsion will occur, so it is good to treat rather than preventing it. In the second case, many cases of 
eclampsia occur without having severity signs and symptoms; As a result, it is difficult to say eclampsia is the 
direct progression of severe preeclampsia. In general, it is impossible to predict eclampsia and the better option 
is giving magnesium sulphate prophylaxis for all types of preeclampsia to prevent ecalampsia. 
The aim of this review was to assess the effect of magnesium sulphate prophylaxis on preeclamptic 
mothers in light of disease progression and adverse outcomes 
 
METHODS  
Searching strategy  
A comprehensive computer-based search of the published work was done in, , PubMed/MEDLINE, HINARI and 
Google scholar using the combination of MeSH (for PubMed) and key terms.  The bibliographic lists of searched 
articles were also used to further retrieve other articles. Date restriction was not applied and all possible studies 
from the inception of the data bases were considered. The search terms include: ‘hypertension’, ‘hypertensive 
disorders’, ‘preeclampsia’, ‘mild/moderate/severe preeclampsia’, ‘eclampsia’, ‘convulsion’, ‘seizure’, 
‘magnesium sulfate’, ‘magnesium sulphate’, ‘pregnancy’, ‘randomized controlled trials’. These terms were 
combined with the Boolean Logic (AND, OR and NOT) in different possible ways. 
Inclusion criteria 
We included interventional (randomized control trials and quasi-experimental studies) and observational studies 
(cohort, case control and case series). Studies that assessed the effect of magnesium sulphate on prevention of 
eclampsia and maternal and perinatal birth outcomes and published only in English language were included.  We 
included mothers who received magnesium sulphate prophylaxis in the prepartum, intrapartum and postpartum 
phases and all stages of preeclampsia (mild, moderate and severe) were considered.  Only studies comparing 
magnesium sulphate with placebo or with no magnesium sulphate group were included. We excluded studies 
where women were given magnesium sulphate for another purpose, such as an adjuvant for anaesthesia or to act 
as a tocolytic agent. In addition, studies comparing magnesium sulphate with another alternative anticonvulsants 
were not include 
Study selection 
Study selection was made in three stages. First titles of articles were retrieved according to search terms and 
eligible abstracts were identified. Secondly, the eligible abstracts of the retrieved articles were reviewed. Thirdly, 
all the articles found to be eligible for full document review in the second stage were reviewed in detail. All 
review processes were made according to the inclusion criteria.  
Outcome measures 
We included studies that reported progression of preeclampsia to eclampsia and the effect of magnesium 
sulphate. Thus, primary outcome was eclampsia/progression to severe preeclampsia. Secondary outcomes were 
postpartum haemorrhage, abruption placenta, caesarean section, respiratory depression, maternal death and baby 
death/admittance to intensive care nursery. 
Data abstraction 
After identifying the articles to be reviewed, standardized data abstraction format was developed. The data 
abstraction form included the following information: name of the first author, country of study conducted, study 
period, study design, total number of participants, the control/comparison, outcome or maternal and perinatal 
adverse effects reported. The abstraction was conducted by two independent reviewers and when discrepancies 
observed it was solved by the third reviewer. 
Quality (risk of bias) assessment 
Methodological quality assessing was made by using Newcastle-Ottawa scale and JADAD criteria for 
observational studies and randomized control trials respectively. Assessment of statistical heterogeneity among 
the studies was done by visual inspection of forest plots (i.e. the overlap of the confidence intervals among the 
studies), Chi-squared (assessing the P-value) and by calculating the I-squared statistic.   If the P-value less than 
0.10 and I-squared exceeded 50% and visual inspection of forest plots is indicative, heterogeneity was 
considered to be substantial and reasons for it was sought by doing a subgroup and sensitivity analysis. 
Additionally, Funnel plots and Egger's regression test was used to search the potential publication bias. 
Statistical analysis 
Statistical analyses were performed using Review Manager, version 5.3 (The Cochrane Collaboration) and 
STATA Version 11. For intervention studies we presented quantitative data from individual studies where 
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possible as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. Pooled estimates 
(summary RR with 95% CI) were calculated using random-effect meta-analysis as we considered that there was 
clinical heterogeneity sufficient to expect the underlying effects differed between trials, or there was substantial 
statistical heterogeneity (where I
2
 was greater than 50% or there was a low P-value, less than 0.10 in the Chi2 
test). 
 
RESULTS  
Study selection  
The initial database searching identified 3025 articles by using the predetermined search terms. From the total 
retrieved articles 346 were excluded because of duplication in multiple sources. After screening the titles, 275 
articles were retrieved for abstract review; 198 articles were excluded after reviewing the abstract. Sixty five 
articles were excluded after full document review as the objectives of the studies were not related with the 
interest of the review and at the end 12 articles were included for the final review (Fig 1). 
 
Figure1. Flow diagram showing selection of studies 
Overall, 28002 mothers with preeclampsia were included and the individual studies were conducted in 
American, Asian, European and African countries. About 58% of the studies were randomized control trials; the 
other types of studies include: one quasi-experimental interventional study, two cohort, one case-control and one 
case series [Table 1]. Two studies reported severe preeclampsia as an outcome[13,14] and three studies reported 
eclampsia as an outcome [15,16,17]. Three studies reported on postpartum haemorrhage after receiving 
magnesium sulphate [13,14,18]. Five studies have reported perinatal adverse outcomes in addition to the 
maternal adverse outcomes [10,12,13,17,19]. The maternal adverse outcomes extracted from the review include: 
severe preeclampsia, caesarean delivery, chorioamnionitis, postpartum hemorrhage, occurrence of eclampsia, 
death, placental abruption and duration of labour. Likewise the perinatal adverse outcomes include: apgar scores, 
neonatal death and still birth. Two randomized control trials (n=357) assessed whether magnesium sulfate 
prevents disease progression in women with mild preeclampsia and compared the occurrence of severe 
preeclampsia among mothers who were given magnesium sulphate and  placebo. No difference was observed 
regarding to the progression of mild to severe preeclampsia among the two groups [13,14]. Another three 
randomized control trials (n=23,350) were conducted to determine whether the administration of prophylactic 
intravenous magnesium sulphate reduces the occurrence of eclampsia in women with severe pre-eclampsia and 
in all of the studies women allocated magnesium sulphate had lower risk of eclampsia than those allocated 
placebo [15,16,17]. Postpartum homerrhaege was reported in three studies as an outcome and in two studies 
(n=289) the rate of postpartum hemorrhage was higher among preeclamptic women treated with magnesium as 
compared with those who received no magnesium[14,18], but in one study (n=222, mild preeclampsia cases) 
there was no difference in the rate of postpartum haemorrhage among the two groups [13]. 
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Table 1. General characteristics of studies included in the review and analysis 
SN Author/s  Year  Country  Study design  Population  Intervention  Control  Outcome  
1 Jeffrey C. 
Livingston, Lisa 
W. Livingston, 
Risa Ramsey,  
2003  USA RCT 222 women with 
mild preeclampsia 
Magnesium 
sulphate 
 
Placebo  
 
•  Sever 
preeclampsia. 
• Caesarean 
delivery 
• chorioamnionitis  
• postpartum 
hemorrhage 
• Apgar scores  
2 Coetzee EJ, 
Dommisse J, 
Anthony J. 
1998 South 
africa 
RCT 685 women with 
severe pre-
eclampsia 
Magnesium 
sulphate 
 
Placebo  
 
• The occurrence 
of eclampsia  
 
3 Vern L. Katz, 
Richard Farmer,  
Jeffery A. Kuller 
et.al  
2000 USA Retrospective 
cohort  
53 pregnancies 
complicated by 
eclampsia 
Magnesium 
sulphate 
 
No 
treatment  
• Progress of 
severe 
preeclampsia 
to eclampsia  
4 Magpie Trial 
Follow-Up 
Study 
Collaborative 
Group.  
2007 UK   
 
RCT 3375 preeclamptic 
mothers  
magnesium 
sulphate   
placebo • Death or 
serious 
morbidity at 2 
years  
5 Chen FP, Chang 
SD, Chu KK.  
1995 Taiwan RCT 64severe 
preeclampsia 
mothers  
magnesium 
sulphate  
No 
treatment 
•  Development of 
eclampsia  
6 Sara E. Szal, 
Mary S. 
Croughan-
Minihane, and 
Sarah J. 
Kilpatrick,  
1999 USA Retrospective 
cohort study 
  154 pregnant 
women  
magnesium 
sulfate 
 No 
Treatment  
• Duration of 
labour  
• PPH) 
•  Admittance to 
intensive care 
nursery  
7 Hall D. R. 
Odendaal H. J. 
Smith M.   
2000 South 
Africa 
Case series 318 preeclamptic 
women  
NA NA • Eclampsia and 
related 
complications 
8 Sibai Baha M.  
 
2004 USA 
  
 
RCT 12673Severe 
preeclamptic 
women 
magnesium 
sulphate  
placebo  • Convulsion 
/eclampsia  
9 Andrea G. 
Witlin, Steven 
A. Friedman, 
and Baha M. 
Sibai, 
1997 USA RCT 135 Women with 
a diagnosis of 
mild preeclampsia 
magnesium 
sulphate  
placebo  •  Duration of 
labour and 
complications  
10 Dima Abi-Said , 
John 
F.Annegers, 
Deborah 
Combs-Cuntrell 
et.al 
1997 USA Case-control 66 cases of 
eclampsia 
Magnesium 
sulphate  
control • Prevention of 
eclampsia  
11 Altman D. 
Carroli G. 
Duley  L. et.al  
2002 UK/33 
countries   
RCT 9992 preeclamptic 
mothers  
magnesium 
sulphate  
placebo  • Eclampsia and 
death of the baby 
12 Shamsuddin L, 
Nahar K, Nasrin 
B, et.al  
2005 Bangladish  quasi-
experimental  
study 
265cases of 
eclampsia and 
severe pre-
eclampsia 
in 
intervention 
group 
non-
intervention  
• Maternal and 
neonatal adverse 
Effect 
Meta analysis  
Five randomized controlled trial studies which had similar outcome of interest were selected for meta-analysis to 
determine the pooled estimate for severe preeclampsia/eclampsia. As it is depicted in the forest plot, 
preeclamptic mothers who took magnesium sulphate had 52% lower risk of developing eclampsia as compared 
with the no magnesium sulphate counterparts (RR:0.48, 95% CI:0.28-0.8)). But the studies are heterogeneous as 
it can be seen from the I
2
=72.2%, so it would be difficult to combine and conclude using the pooled estimate 
(Fig.2).  
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Figure 2. The effect of magnesium sulphate prophylaxis in pregnant mothers diagnosed with preeclampsia 
(Forest plot)  
 
Subgroup analysis by outcome type 
One way of managing heterogeneous studies is by conducting subgroup analysis. In this review there are two 
outcomes; severe preeclampsia and eclampsia. When we run separately according to the outcome, the respective 
studies became homogenous (I
2
=0.0% for severe preeclampsia) and (I
2
=39.8 for eclampsia). In this case it is 
possible to combine the studies. As it is depicted in the forest plot in Fig.3 (subgroup analysis), mild 
preeclamptic mothers who took magnesium sulphate have similar risk of developing eclampsia as compared with 
the no magnesium sulphate counterparts (RR: 0.9, 95% CI: 0.53-1.54)). On the contrary, severe preeclamptic 
mothers who took magnesium sulphate have 66% lower risk of developing eclampsia as compared with the no 
magnesium sulphate counterparts (RR: 0.34, 95% CI:0.23-0.48)) (Fig.3). 
NOTE: Weights are from random effects analysis
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Figure 3. The effect of magnesium sulphate prophylaxis in pregnant mothers diagnosed with preeclampsia 
(Subgroup analysis)  
 
Test for publication bias  
Looking for funnel plot asymmetry is one method of checking publication bias but graphic way of checking 
publication bias is recommended when there are more than ten studies, so in this case funnel plot (Figure 4) is 
not the appropriate way of checking publication bias as the number of studies reviewed are limited(n=5). To 
resolve this problem test for statistical significance funnel plot asymmetry was considered which is given by the 
Egger test which shows no publication bias (p=0.62) 
 
Figure 4. Funnel plot to check publication bias for the effect of magnesium sulphate on preeclampsia 
Sensitivity analysis 
NOTE: Weights are from random effects analysis
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Sensitivity analysis helps to determine whether individual studies are affecting the overall estimate. If 
there is single study affecting the overall review, it means that the review is sensitive. If the individual studies 
are not affecting the overall estimate it means that the review is not sensitive. As it can be seen from figure 5, 
whenever each study is removed the pooled estimate, doesn’t vary much (0.48) 
 
Figure 5. Sensitivity analysis for the effect of magnesium sulphate on preeclampsia 
 
Discussion  
A systematic review and meta-analysis was conducted to assess the effect of magnesium sulphate prophylaxis on 
preeclamptic mothers in light of disease progression and adverse outcomes. In this review magnesium sulphate 
prophylaxis was found to be protective against eclampsia development when given to severe preeclampsia cases 
which is congruent with the WHO recommendation of providing magnesium sulphate prophylaxis for severe 
preeclampsia and eclampsia cases [20]. On the other hand, according to this review magnesium sulphate 
prophylaxis has no effect in the prevention of disease progression in mild preeclampsia cases, in contrary to this 
finding; a systematic review  on descriptive studies by  Brhane Y. revealed that a significant number of 
eclamptic women had either normal blood pressure or mild-to-moderate hypertension immediately before 
seizure which means the findings were in support of initiating magnesium sulfate prophylaxis to all women with 
mild pre-eclampsia[11]. The discrepancy may be due to the difference in the study designs; the current review 
pooled two randomized control trial results but the previous review qualitatively summarized descriptive studies. 
This review implies that there are only limited randomized control trials conducted so far to assess the effect of 
magnesium sulphate on mild preeclampsia cases suggesting the need to have large randomized control trials to 
investigate the case. 
In the current systematic review, the reviewed studies reported that mothers having severe preeclampsia 
and given magnesium sulphate prophylaxis had higher chance of developing postpartum haemorrhage as 
compared with those who were given no magnesium sulphate prophylaxis. This shows, though the exact 
mechanism of magnesium sulphate is unknown it has tocolytic effect (relaxes the uterus) which leads to poor 
contraction in the postpartum period which may in turn lead to severe postpartum haemorrhage [21].  
In the current review magnesium sulphate prophylaxis was found to be associated with some adverse 
outcome (PPH) but no difference observed in other maternal and perinatal adverse outcomes. In other literatures 
postpartum hemmorhage is not frequently described as adverse outcome of magnesium sulphate a part from 
respiratory depression and weakening of reflexes which implies less emphasis given to this part. Cognizant to the 
serious consequences of postpartum hemmorhage this study revealed the important causations to be taken in to 
consideration while providing magnesium sulphate as a prophylaxis and treatment for severe preeclampsia and 
eclampsia cases respectively. 
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Strength and limitations  
Strength 
• Majority of the studies reviewed are randomized controlled trials and it covers large sample size. 
 
Limitations 
• Only articles published in English language were considered 
• Unpublished/grey literature were not included 
 
Conclusion  
From this systematic review and meta-analysis it can be concluded that magnesium sulphate prophylaxis 
provision for mild preeclampsia cases has no value in preventing severe preecalampsia though the studies 
reviewed are limited to reach in a plausible conclusion. On the other hand magnesium sulphate prophylaxis 
given for sever preeclampsia is found to be effective in preventing eclampsia/convulsion.  Health professionals 
should keep magnesium sulphate for severe preeclampsia and eclampsia cases only and they should be aware of 
the adverse effects of magnesium sulphate especially post partum haemorrhage while providing the drug for 
prevention and treatment purposes. 
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